Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label iPSCs. Show all posts
Showing posts with label iPSCs. Show all posts

Monday, November 19, 2018

Parkinson’s Patient Transplanted with Neurons Derived from iPSCs

So what the fuck followup is being done by your doctor and stroke hospital to get stroke research initiated? Or are they twiddling their thumbs again waiting for SOMEONE ELSE TO SOLVE THE PROBLEM?  2.4 million is minor, I lost at least 5.571 billion neurons out of 80 billion in total. And if the 5 causes of the neuronal cascade of deathhad been stopped in the first week, I would have only lost 171 million. That I could have easily recovered from.


 

 

Parkinson’s Patient Transplanted with Neurons Derived from iPSCs


This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

Nov 14, 2018
Ashley P. Taylor

78
ABOVE: © ISTOCK.COM, MUZON
In October, researchers at Kyoto University transplanted cells generated from induced pluripotent stem cells into the brain of a man with Parkinson’s disease, the scientists reported Friday (November 9) at a press conference. This is the first time that researchers have tested the use of iPSCs in the human brain, and Parkinson’s disease is only among a handful of conditions for which iPSC-based therapies have been tested in humans at all, Nature reports.
In Parkinson’s disease, cells that produce the neurotransmitter dopamine die off, resulting in tremors and other movement problems. Although there are treatments that can alleviate some symptoms, there is currently no cure for the disease.
The transplanted cells in this treatment are precursors to dopamine-producing neurons, and the hope is that they will restore the dopamine deficit and relieve symptoms. A very similar procedure reduced movement difficulties in monkeys whose dopaminergic neurons had been experimentally poisoned to model Parkinson’s disease.

See “First iPS Cell Trial for Heart Disease Raises Excitement, Concern

Kyoto University stem cell researcher Jun Takahashi and colleagues began with a stock of iPSCs, which they had previously reprogrammed from an anonymous donor’s skin cells. They then differentiated the iPSCs into dopaminergic-neuron precursors. In a three-hour surgery, neurosurgeon Takayuki Kikuchi implanted 2.4 million of the precursor cells into 12 sites in the brain.
“The patient is doing well and there have been no major adverse reactions so far,” Takahashi tells Nature. If all goes well, in six months doctors will implant another dose of neurons into the patient’s brain.
In the future, the researchers plan to give the treatment to six other Parkinson’s disease patients.
“The best scenario is to see patients improve to the extent they do not have to take any medicine,” Takahashi tells The Japan Times.

Sunday, November 3, 2013

Resetting stem cells

This seems like our stroke researchers could use this to jumpstart creation of new neural stem cells. Ask your doctor what researchers they are going to contact to get this research  into a stroke protocol. You do expect your doctor to know at least a dozen stroke researchers? Don't you?
http://blogs.plos.org/biologue/2013/11/01/a-faster-reset-button-for-stem-cells/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+plos%2Fblogs%2Fbiologue+%28Blogs+-+Biologue%29

Friday, February 8, 2013

Scientists announce new iPSCs-based treatment for myelin disorders

But first ask your doctor what damage your stroke caused to your myelin. Then you can ask what protocol there is to correct that.

Scientists announce new iPSCs-based treatment for myelin disorders


Researchers from the Rochester Medical Centre (URMC) released a new study today, where they exhibit for the first time, that neural stem cells derived from human induced pluripotent stem cells (hiPSCs) may hold the key for treating one day myelin-related conditions, like multiple sclerosis and various rare pediatric leukodystrophies.

In this animal study the researchers, led by Steven Goldman, were successful in creating myelin-producing cells. As aforementioned, the cells were created from an hiPSC line which in turn was derived from human skin cells. Goldman said that their study not only suggests that an hiPSC based treatment would be effective for myelin disorders but it also indicates that cells derived from iPSCs seemed to be more effective then the ones derived from embryonic stem cells.

According to the researchers, the study has great implications in the field of treating neurological conditions resulting from myelin loss. Myelin is an insulating material which forms a layer called the myelin sheath, which in turn plays an important role in the proper function of the central nervous system. Some indicative examples of such conditions are multiple sclerosis and a few extremely rare pediatric and commonly fatal conditions called pediatric leukodystrophies.

Myelin is produced by oligodendrocytes a type of cell derived from neural stem cells (NSCs). It has long been hypothesised that myelin-related conditions may be treatable with therapies that would introduce a "fresh" population of healthy neural stem cells that in turn would differentiate into oligodendrocytes regenerating the lost myelin.

Friday, April 6, 2012

Engineering neural stem cell fates with hydrogel design for central nervous system regeneration

Someone is thinking ahead and trying to solve the problems with stem cells in the brain.
http://www.sciencedirect.com/science/article/pii/S0079670012000202

Abstract

Injuries and disease to the central nervous system (CNS) are accompanied by severe consequences, as the adult CNS has very limited capacity to replace the lost neural cells. Different sources of neural stem cells for CNS tissue regeneration exist, including embryonic stem cells (ESCs), fetal stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs), and so on. However, before stem cell therapy can be a viable option for treatments, many issues still need to be resolved, including low viability, lack of control of stem cell fate, and low cell engraftment after transplantation. Though controlling these parameters is extremely challenging, engineering structures that create permissive niches for the transplanted cells, such as the use of biocompatible hydrogels, is a promising approach. This review will focus on highlighting existing hydrogel systems currently being investigated for CNS tissue regeneration, as well as discuss design criteria for hydrogels and methods for manipulating stem cells within hydrogels systems. Finally, the use of these hydrogel systems as carriers for stem cell transplantation in CNS injury and disease models will be discussed.